A treatable Congenital Disorder of Glycosylation with no central nervous system involvement.By: Fiona Waddell, journalist and patient
Reviewed by: Vanessa Ferreira, Volunteer APCDG (www.apcdg.com)
Posted: Thursday, May 25, 2016
Request a scientific publication at: email@example.com
Sunnie Yan-Wai Wong, BA, MD/PhD Candidate at Tulane University School of Medicine (New Orleans, USA) created with her team a rating scale to evaluate measurable clinical features of PGM1-CDG (former CDG It). This is important for early recognition and diagnosis, which is essential for proper management and improving clinical outcome.
When this enzyme is not working, there may be a variety of clinical manifestations, including hypoglycaemia, congenital malformations, early-onset of dilated cardiomyopathy, growth retardation, hormonal deficiencies, hepatopathy, haemostatic anomalies and myopathy. Interestingly, PGM1-CDG is one of the few CDG's that has no central nervous system involvement and has been clinically shown to be tratable; therefore, early diagnosis is important.
Wong evaluated 27 patients with PGM1-CDG who were divided into 3 phenotype groups: severe, moderate and mild. She and her team developed a scoring system, the Tulane PGM1-CDG Rating Scale (TPCRS). This scale evaluates PGM1-CDG disease severity based on the patients' clinical history and presentation. They examined the relationship between genotype, enzyme activity and the TPCRS score.
The research showed that there was a great diversity in the phenotype spectrum. Hepatopathy is the most frequent clinical manifestation, followed by hypoglycaemia, congenital malformation and growth retardation. It also showed that genotype and enzyme activity does not have any significant correlation with the TPCRS score. There were 5 clinical features identified that are strongly associated with one another and are predictive of disease severity: congenital malformation, cardiac involvement, endocrine deficiency, myopathy and growth. Congenital malformation and growth retardation can be evaluated by physical examination, without the need for specific diagnostic testing and thus allow for rapid assessment and initiation of therapy.
It is important to note that long-term follow-up data are not available for some of the patients and disabling symptoms may appear later with time. Although liver involvement and haemostatic anomalies do not have clear correlations with disease severity, these clinical features are common in PGM1-CDG and require timely and proper treatment. The TPCRS can be repeated on patients over time, for monitoring disease progression and responsiveness to therapeutic treatment.
Keywords:Phosphoglucomutase-1 deficiency, PGM1-CDG, Tulane PGM1-CDG Rating Scale, TPCRS, Congenital Disorders of Glycosylation (CDG).
Information for families:
Literature used to prepare the news:
To request an article, please write to firstname.lastname@example.org
Image courtesy of Stuart Miles at FreeDigitalPhotos.net
Write something about yourself. No need to be fancy, just an overview.